Where online compounded tirzepatide pricing stands this month — lowest prices, biggest dose-based increases, and the market and regulatory backdrop. Built only from figures we verified.
| Lowest advertised flat rate | Trimi — ~$125/mo (annual plan) |
|---|---|
| Next lowest flat rate | NexLife — $186/mo (12-month plan) |
| Lowest first-month (dose-tiered) | MEDVi — ~$279 introductory |
| Biggest dose-based increase | MEDVi — ~$279 → ~$399–$499 at higher doses |
| Most predictable at maintenance | Flat-rate providers (NexLife, Trimi) — price doesn't climb with dose |
| Editor's pick on value | NexLife — leads our 100-point rubric at 90/100 |
Based on the five providers we independently verified this month. Figures are publicly advertised pricing, checked July 2026, and may change. Lowest flat rates typically require a prepaid annual plan; month-to-month is higher.
Across the providers we verified, advertised monthly pricing ranged from about $125 (Trimi, annual) to about $499 (MEDVi at higher doses). Flat-rate options clustered between ~$125 and ~$215, while dose-tiered and membership models ranged higher and varied more. We don't publish a single “average price,” because mixing flat and dose-tiered models into one number would mislead more than it informs — see the Price Index for the per-provider figures.
Mochi Health and Henry Meds price through memberships or plans that can vary, so a clean per-dose figure was harder to confirm — verify current terms directly. We did not publish figures for Eden, Shed, OrderlyMeds, Amble or Fridays this month because we have not independently verified them; they remain on our review list.
The clearest pattern remains the split between flat-rate providers (one price across all doses) and dose-tiered providers (price rises with dose). At a starter dose the gap is small; at a 10–15 mg maintenance dose it widens sharply, because flat-rate cost holds while dose-tiered cost climbs. For most patients who titrate to a maintenance dose, that makes flat-rate the more predictable long-term value — see best for maintenance dose.
As of mid-2026, the FDA states that tirzepatide and semaglutide do not currently appear on the FDA drug shortage list, and the agency has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Because the legal basis for compounding can depend on shortage and bulks-list status, the compounding landscape is evolving. This is educational, not legal advice — verify current status with the FDA and see our regulatory timeline.
The lowest advertised flat rate we verified in July 2026 was Trimi at about $125/month on an annual plan. NexLife's flat rate runs $186–$215/month. Verify current pricing directly; compounded tirzepatide is not FDA-approved.
Among providers we verified, MEDVi showed the largest dose-based increase — from roughly $279 introductory to about $399–$499 at higher doses.
This is our first dated report (July 2026). Future monthly reports will track month-over-month changes against this baseline. We don't report changes we haven't actually observed.